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ABSTRACT
Glioblastoma (GBM) still remains an incurable disease being radiotherapy (RT) 
the mainstay treatment. Glioblastoma intra-tumoral heterogeneity and Glioblastoma-
Initiating Cells (GICs) challenge the design of effective therapies. We investigated 
GICs and non-GICs response to RT in a paired in-vitro model and addressed molecular 
programs activated in GICs after RT. Established GICs heterogeneously expressed 
several GICs markers and displayed a mesenchymal signature. Upon fractionated RT, 
GICs reported higher radioresistance compared to non-GICs and showed lower α- and 
β-values, according to the Linear Quadratic Model interpretation of the survival curves. 
Moreover, a significant correlation was observed between GICs radiosensitivity and 
patient disease-free survival. Transcriptome analysis of GICs after acquisition of a 
radioresistant phenotype reported significant activation of Proneural-to-Mesenchymal 
transition (PMT) and pro-inflammatory pathways, being STAT3 and IL6 the major 
players. Our findings support a leading role of mesenchymal GICs in defining patient 
response to RT and provide the grounds for targeted therapies based on the blockade 
of inflammatory pathways to overcome GBM radioresistance.
INTRODUCTION
Glioblastoma (GBM) is the most common malignant 
type of adult primary brain tumor and is characterized 
by extreme therapeutic resistance that leads to poor 
patient outcome [1]. Radiation therapy (RT) has been the 
cornerstone of GBM treatment and still is the common 
mainstay therapeutic approach in the majority of patients 
[2]. The inability of conventional treatment to achieve 
durable remissions makes GBM an incurable disease [3, 
4].
The heterogeneous nature of GBM results not only 
from genomic dissimilarities among different patients 
(intertumoral heterogeneity) but also from the plethora of 
cells composing the same specimen and showing different 
molecular characteristics and capacities to proliferate, 
migrate, invade [5] and sensitivity to treatment [6-8] 
(intratumoral heterogeneity). Likewise, GBM harbor a 
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relative small population of cells showing stem properties 
[9, 10] defined as Glioblastoma-Initiating Cells (GICs), 
which are key contributors to treatment failure and poor 
patients outcome [11]. Several markers have been defined 
to isolate GICs from the bulk of the tumor: CD133, 
encoded by PROM1 [12], CD44 [13], L1CAM [14] or 
ITGA6 [15]. Among them, CD133 is the most widely 
used, although a clear consensus on a unique marker or 
a combination of them to unequivocally identify GICs is 
still not available [16]. CD133+ GICs have been associated 
with radioresistance due to preferential activation of 
DNA-damage-response pathways [17, 18]. However, the 
over-reliance on CD133 as a unique marker of GICs led 
to contradictory results regarding stem properties [19, 20] 
and sensitivity to radiotherapy [21, 22] of CD133- cells. 
Finally, transcriptomic analysis revealed four different 
GBM subtypes: Proneural (PN), Neural, Classical and 
Mesenchymal (Mes) [23]. Among them, tumors with a 
Mes gene signature are predominantly primary and, in 
some studies, show a more aggressive trend and greater 
resistance to radiation therapy than PN [24-26]. 
The purpose of this study was to address the relation 
between GICs and cell radioresponse, irrespective of any 
GICs marker expression. We established an in-vitro model 
with paired unsorted GICs and non-stem Differentiated 
Glioblastoma Cells (DGC) obtained from the same patient. 
Our established GICs displayed a clear Mes signature and 
when compared to DGCs counterpart, GICs were found 
to be more radioresistant to fractionated RT. In addition, 
we identified a direct correlation between in-vitro GICs 
radioresistance and patient outcome. Finally, we observed 
preferential upregulation of Mes markers and inflammation 
pathways in GICs acquiring a radioresistant phenotype. 
Our work contributes to improved understanding of the 
mechanisms involved in GBM radioresistance and may 
help point the way to the development of new therapeutic 
strategies for GBM patients.
RESULTS
Establishment of an in-vitro model of intratumoral 
GBM heterogeneity
GBM cell heterogeneity results from a wide-range 
of features including differences between DGC within the 
tumor bulk and GICs [27]. To analyze differences between 
these two cellular compartments and evaluate their 
response to radiotherapy, we generated an in-vitro model 
from 12 newly diagnosed GBM IDH1-wt tumors (GBT) 
(Figure 1A). Tumor cells from each patient were grown 
as both neurospheres and FBS-differentiated cultures to 
enrich for GICs and DGC, respectively. Six GICs/DGC 
culture pairs were successfully established and maintained 
in-vitro (GBT35, GBT82, GBT88, GBT90, GBT94 and 
GBT104).
We assessed whether the molecular profile of 
primary tumors was conserved during cell culture 
analyzing both, original tumor tissues and neurosphere-
derived cultures, according to molecular subtype 
classification (Mesenchymal, Mes; and Proneural, 
PN). Using a set of four PN (SOX9, OLIG2, SOX2 and 
PROM1) and four Mes (FN1, CHI3L1, CD44 and CTGF) 
genes, we calculated the metagene score of each sample. 
All GBT exhibited a Mes score, which was maintained 
in neurosphere cultures (Figure 1B and Supplementary 
Figure S1A). Positive controls, with strong PN and Mes 
profiles, were included (Supplementary Figure S1B). 
Evaluation of MGMT promoter methylation status and 
major genomic alterations in primary tumor samples and 
the corresponding patient-derived culture pairs revealed 
consistent findings (Supplementary Figure S1C and S1D). 
Taken together, our results show that patient-derived 
cultures retained genetic characteristics of the original 
tumor.
Cultured GICs express cancer stem cell (CSC) 
markers and display CSC functional features
To validate our neurosphere cultures as significantly 
enriched in GICs, we first analyzed their proliferative 
capacity by means of soft-agar assay and plating efficiency 
assay. GICs were more capable to proliferate at low cell 
density than their monolayer counterparts (Figure 1C, 1D 
and Supplementary Figure S2A). Primary neurosphere 
cultures also reported great capacity to self-renew 
independently of any paracrine stimuli and to undergo 
differentiation toward all CNS lineages (Supplementary 
Figure S2B and S2C). Finally, neurospheres were 
injected orthotopically in nude mice. By 7 weeks, 
histological analysis of xenografts revealed pathological 
features comparable to corresponding parental tumors 
(Supplementary Figure S2D). 
We then evaluated a set of GIC markers in GICs/
DGC culture pairs: CD133, CD44, L1CAM and ITGA6. 
GICs reported significant greater expression of PROM1, 
L1CAM and ITGA6 at both mRNA and protein level, 
being selected markers almost undetectable in DGC 
(Figure 1E, 1F, Supplementary Figure S3A and S3B). 
Immunofluorescence staining was consistent with 
previous results (Supplementary Figure S3C). In addition, 
we identified within neurosphere cultures multiple 
clones expressing either L1CAM, ITGA6, CD44 or a 
combination of them, thus supporting GICs heterogeneity. 
Taken together, our results confirm that our primary 
neurosphere cultures were enriched in GICs and retained 
high level of heterogeneity.
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Figure 1: Establishment and characterization of the in-vitro model. A. Clinical data of patients. M, male; F, female; DFS, 
disease-free survival; OS, overall survival; na, not analyzed (sample not available). * sudden death not related with GBM. B. Comparative 
heatmap of the molecular signature. Metagene score was calculated for each sample and compared to others after Z-score correction. Grey 
shade: undetermined data. C. Soft Agar assay performed in both culture conditions. The number of colonies scored was plotted respectively 
to the number of cell seeded (n = 9, *P < 0.05, **P < 0.01, ***P < 0.001, Mann-Whitney test). D. Plating efficiency of DGC and GICs 
cultures. Data are plotted as mean growth ratio for either colonies or neurospheres in reference to cells seeded (n = 4, ***P < 0.001, Mann-
Whitney test). E. Real-time PCR analysis of the GICs marker PROM1 (n = 4, *P < 0.05, **P < 0.01, ***P < 0.001, unpaired t-test). F. 
Western blot analysis of CD44, ITGA6 and L1CAM GICs markers. 
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Figure 2: GICs exhibited higher radioresistance compared to DGC. A. Survival curves after RT (n = 4, two-way ANOVA). 
Data are plotted in Log (2) scale. B. Survival curves and LQM parameters to quantify radiation sensitivity. SF2 and SF8 are indicated as 
mean ± SEM. (1) Calculated by the ratio α-DGC/α-GICs. (2) Calculated by the ratio β-DGC/β-GICs. SF2, surviving fraction at 2 Gy; SF8, 
surviving fraction at 8 Gy; AUC, area under the curve. C. Correlation plots among α- and β-values calculated for analyzed cultures and 
matching patient DFS and OS. 
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GICs intrinsic radioresistance is greater than 
DGC
We next evaluated our patients-derived culture pairs 
responses to radiotherapy. We treated both DGC and GICs 
with fractionated RT at a dose of 2 Gy/day up to 8 Gy 
to simulate clinical radiotherapy regimens, and radiation 
response was evaluated by clonogenic assay (Figure 2A). 
Data of surviving curves were interpreted according to the 
Linear Quadratic Model (LQM) [28] by means of α- and 
β-values at 2 Gy. In terms of radiobiological meaning, α- 
and β- values correspond to intrinsic radiosensitivity and 
to repair capacity, respectively [29]. We detected different 
degrees of radiosensitivity among the evaluated GICs, 
being PG90-GICs the most radioresistant and PG35-GICs 
the least (Figure 2B). Interestingly, in three out of four 
culture pairs analyzed, GICs showed higher SF2, SF8 and 
AUC compared to DGC, suggesting a more radioresistant 
phenotype (#82, #88 and #90; P < 0.001). Likewise, the α- 
and β-parameters of GICs compared to their corresponding 
DGCs were markedly lower, indicating greater intrinsic 
radioresistance and capacity to repair radiation-induced 
DNA damage, respectively. 
Intrinsic radioresistance of GICs predicts clinical 
outcome
Next, we compared the LQM parameters obtained 
from each culture pair with the corresponding patient 
disease-free survival (DFS) and overall survival (OS). 
All patients were managed according to Stupp regimen 
[30]. Interestingly, we observed a significant correlation 
between patient’s DFS and its matching GICs α- and 
β-values (Bilateral Spearman’s rho P < 0.01): the smaller 
the α- and β-, the shorter the patient’s DFS (Figure 
2C). In addition, patient GBT35, whose GICs culture 
displayed the highest α- and β-values, was the unique 
patient with complete response after concomitant RT and 
Temozolomide. Regarding OS, we also found a positive 
association with each patient α- and β-values. On the 
contrary, α- and β-parameters of the corresponding DGC 
compartment did not correlate with patient outcome. 
Taken together, these findings suggest that the overall 
clinical response to fractionated RT might rely more on 
the intrinsic radiosensitivity of their GICs subpopulation. 
Exposure of GICs to repeated cycles of RT 
promotes the acquisition of radioresistance
Then, we analyzed GICs responses to repeated 
cycles of RT. For these analyses, we chose the most 
radiosensitive culture pair established. PG35-DGC/GIC 
were exposed to standard 4-day cycle of fractionated 
doses scheduled every 3 weeks (Figure 3A). The 
recovery period within cycles was calculated according 
to complete restoration of the doubling time (data not 
shown). Following the first recovery period, cultures were 
named #35R where R stands for one completed cycle of 
radiation and recovery. Subsequently, PG35-DGC-R and 
PG35-GICs-R underwent a second cycle of radiation and 
recovery period (#35-RR). Finally, P#35-RR were treated 
with a third cycle of RT. Interestingly, the survival curve 
obtained from PG35-GICs-R revealed a significant switch 
toward a more radioresistant phenotype (Figure 3B). 
When compared to PG35-GICs, PG35-GICs-R displayed 
significantly higher SF2 and SF8 (P < 0.0001) with an 
overall statistical difference between the two curves 
(two-way ANOVA P < 0.0001; Figure 3C). Moreover, 
PG35-GICs-R curve showed an important reduction in 
α- and β-values at 2 Gy indicating increased intrinsic 
radioresistance and greater repair capacity, respectively. 
In contrast, PG35-DGC-R showed no statistical variation 
of SF2 or SF8 (P = 0.5 and P = 0.1, respectively). 
Comprehensively, PG35-GICs-R reported a significantly 
more radioresistant curve than PG35-DGC-R (P < 0.0001). 
Finally, after the third radiation cycle, PG35-DGC-RR 
reported dramatic radiosensitization (P < 0.0001) with a 
striking drop in SF8 (P < 0.0001), whereas PG35-GICs-
RR maintained the acquired radioresistant phenotype 
(Figure 3B and 3C). In conclusion, repeated cycles of 
fractioned RT induced opposite responses in PG35-DGC 
and PG35-GICs based on the acquisition of different 
grades of radiosensitivity, which makes an attractive 
model for the study of determinants and regulators driving 
GICs acquired radioresistance. 
RT-induced radioresistant GICs predominantly 
express genes involved in inflammation, migration 
and EMT
Transcriptomes from fourteen samples representing 
five different #35 experimental conditions were analyzed 
using Human Gene 1.0 ST Array. PCA was conducted 
to visualize the overall transcriptome status of analyzed 
conditions (Figure 3D). Two major clusters reflecting 
culturing conditions but not irradiated status were 
identified: cluster_1 composed of PG35-DGC CT and 
RT samples, and cluster_2 composed of PG35-GICs CT 
and RT. Interestingly, irradiated PG35-GICs-R displayed 
a strong segregation from the above-mentioned clusters, 
thus defining a third cluster. 
Comparative analysis of transcriptomes between 
CT and RT samples within the same cluster did not 
identify significant changes in gene expression (FDR 
< 0.05). However, GSEA identified some significant 
associations: after RT, DGC showed positive associations 
with inflammatory pathways and negative associations 
with several processes highlighting deregulation of cell-
cycle and of chromosomal stability (Supplementary 
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Figure 3: Generation of a radioresistant clone. A. Schedule of the repeated cycles of fractioned RT carried out on #35 culture pair. 
B. Clonogenic assay survival curves after second (left) and third (right) radiation cycles. Data are plotted in Log(2) scale. Black and grey 
dashed lines represent PG35-DGC and PG35-GICs survival curves respectively and were included as internal reference (n = 4, two-way 
ANOVA calculated comparing PG35-DGC-R to PG35-GICs-R and PG35-DGC-RR to PG35-GICs-RR). C. Survival curves and LQM 
parameters. D. Genome-wide transcriptomic analysis of microarray data using unsupervised PCA plot. CT, control; RT, 8 Gy irradiated.
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Figure S4). Single-treated GICs also displayed positive 
association with inflammatory pathways but unlike DGC, 
any pathway reported negative associations below FDR < 
0.05 or nominal p-values < 0.05. 
To identify determinants of the radioresistant 
switch, irradiated PG35-GICs-R (cluster_3) was 
compared to cluster_2. GSEA-BioCarta identified several 
positively enriched pathways related to inflammation 
processes (Supplementary Figure S5), with IL6, IL8 
and CSF3 among the genes with the highest scores 
(Supplementary Table S1). KEGG and Reactome 
databases highlighted enrichment of pathways regulating 
migration, Extracellular-Matrix (ECM) remodeling and 
cell-to-cell or cell-to-ECM interaction (Supplementary 
Figure S5). To gain more insight into the biological 
significance of our results, GSEA was interrogated 
through the Hallmark collection. Interestingly, genes 
associated with Epithelial-to-Mesenchymal Transition 
(EMT) and with the inflammatory response mediated by 
TNF-α, IFN-γ, IFN-α and IL-6 were the most enriched in 
double irradiated PG35-GICs (Figure 4A). To determine 
whether repeated radiation cycles induced a global shift 
in PG35-GICs toward a more Mes transcriptome, a GSEA 
on PN and Mes signatures obtained from TCGA network 
[23] was performed. Strikingly, cluster_3 compared to 
cluster_2 exhibited a highly significant enrichment of the 
mesenchymal signature (FDR < 0.001), but not of the PN 
one (FDR = 0.94; Figure 4B).
Finally, to identify which transcription factor (TF) 
might be involved in the observed transcriptional changes, 
a GSEA-TFT analysis was performed. Interestingly, the 
most significantly enriched TF in cluster_3 compared to 
cluster_2 were key TFs driving the PMT [24, 31], such 
as STAT3 , NF-κB and C/EBPβ (Figure 4C and 4D). 
To validate the activation of STAT3, phosphorylation in 
Tyr705 and Ser727 was evaluated. Interestingly, upon 
RT PG88-GICs and PG90-GICs (the more radioresistant 
cultures) showed a significant phosphorylation increase at 
Y705, but not at S727 residues, recently correlated with 
STAT3 mitochondrial functions [32] (Figure 4E). 
GICs upregulate a defined set of genes with 
prognostic value upon radiation
To verify the reliability of microarray findings, a 
panel was compiled based on the most upregulated genes 
with FDR < 0.05 and on their contribution to PMT and 
inflammatory pathways (Figure 5A). The induction of 
these genes was confirmed by q-PCR in #35 culture pair 
immediately after fractionated 8 Gy and 16 Gy (#35-R). 
After the second cycle of RT the whole genes increased 
their expression in GICs but not in DGC (Figure 5B). 
Other analyzed culture pairs reported comparable 
findings (Figure 5B). Next, to further explore the IL6/
STAT3 pathway, we analyzed the expression of IL6Rα. 
Consistently with previous findings [33], all GICs 
reported either higher IL6R baseline expression or greater 
induction following RT (Figure 5C). We also found a good 
correlation between the defined panel with the GBM Mes 
subtype (Supplementary Figure S6A and S6B) and patient 
outcome (Supplementary Figure S6C). Taken together, 
these findings identify pathways, processes and specific 
genes related to mesenchymal GICs influencing GBM 
radiotherapy response and clinical outcome.
DISCUSSION
Given the intratumoral heterogeneity and the 
increasing relevance of GICs in GBM recurrence [11], 
in this study we sought to develop an in-vitro model to 
investigate molecular mechanisms underlying GBM 
radioresistance based on these major cornerstones.
Despite the historical relevance of CD133 as a 
GIC marker [10], several studies have demonstrated that 
GBM cells lacking CD133 are unexpectedly capable 
of tumor initiation [19, 20]. Consequently, to avoid the 
underestimation of the stem pool and better preserve 
the heterogeneity of GICs, we chose the neurosphere 
culture method [9]. Established GICs clearly display 
mesenchymal traits, greater clonogenic capacity, have 
greater self-renewal and tumorigenic capability, and 
express more L1CAM, CD44, CD133 and ITGA6 
compared to the non-GIC tumor bulk cells. Importantly, 
GICs display a heterogeneous compartment characterized 
by multiple clones. 
Bao and colleagues reported higher radioresistance 
of CD133+ GICs when compared to CD133- [17]. Yet, 
the simplified association between stemness and CD133 
expression might have led to misinterpretations, since 
other studies analyzing CD133+ versus CD133- found 
contradictory results [21, 22]. In our study, we demonstrate 
that all GIC-enriched cultures, established irrespectively 
of the expression of any stem cell marker, ended up being 
more radioresistant than their differentiated counterparts. 
Other groups investigated response to RT on similar 
paired culture systems, but the evaluation through 
cytometry-based analysis shortly after RT probably led to 
an underestimation of the RT long-term effects [34] and 
to claim a lack of significant difference between GICs 
and non-GICs cultures [35, 36]. Most importantly, we 
found that LQM parameters of GICs cultures positively 
correlated with patient outcome: the smaller the α- and 
β-values of GICs, the shorter the DFS of the matched 
patient. Although further studies with a wider cohort of 
paired samples is required, our findings support the key 
role of GICs in defining patient treatment response to RT. 
The transcriptomic analysis of irradiated samples 
allowed us to identify molecular determinants associated 
with the acquisition of PG35-GICs-R radioresistance. 
Microarray analysis revealed a marked upregulation 
of pathways related to inflammation, PMT, ECM 
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Figure 4: Transcriptomic analysis of radioresistant PG35-GICs-R. A. List of GSEA Hallmark gene sets significantly enriched 
in cluster_3 compared to cluster_2 ranked according to NES. GSEA significance level: FDR < 0.05. NES, normalized enrichment score; 
FDR, false discovery rate. B. GSEA enrichment plot of Mes and PN Verhaak signatures [23]. C. Top twenty TF gene sets significantly 
activated in cluster_3 compared to cluster_2 ranked according to NES (FDR < 0.05). D. GSEA enrichment plot of C/EBPβ-associated 
gene sets. Individual NES and FDR were reported. E. Analysis of STAT3 phosphorylation following RT. Representative western blot and 
pSTAT3(Y705) and pSTAT3(S727) bands quantitation (n = 3, *P < 0.05; **P < 0.01, unpaired t-test).
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Figure 5: PMT and inflammation are preferentially activated in GICs following RT and correlate with patient 
outcomes. A. Panel of genes selected to validate microarray data ranked according to R-fold (FDR < 0.05). B. Unsupervised hierarchical 
clustering of panel expression following fractionated RT and control condition. Data from #35 (left) and #82, #88, #90 (right) are depicted. 
C. IL6Rα expression in primary cultures (n  = 3, *P < 0.05; ***P < 0.001, unpaired t-test comparing data to DGC CT; $$P < 0.01; $$$P < 
0.001, unpaired t-test comparing data to corresponding control).
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remodeling and cell migration. It is well known that 
beyond the induction of DNA damage, IR triggers 
complex inflammatory cascades in tumor and immune 
cells inducing the expression of interleukins (IL1, IL6, 
IL8, TNF-α) [37], adhesion molecules (ICAM-1, VCAM) 
[38] and activation of NF-kβ pathway, the central linker 
between inflammation, carcinogenesis and radioresistance 
[37, 39]. Apart from NF-kβ, STAT3 is a further 
inflammatory molecule activated by RT playing a crucial 
role in radioresistance of tumors [40-42]. The involvement 
of STAT3 in GBM radioresistance [43], lead us to analyze 
the STAT3 phosphorylation status following RT. Indeed, 
we detected RT-dependent activation of STAT3-pY705 
in our established GICs. Moreover, IL6/JAK/STAT3 
and TNF-α/NF-kβ pathways were significantly activated 
following RT, indicating and activation of inflammatory 
genes upon radiation. Thus, targeting the inflammatory 
signaling pathways induced by IR offers the opportunity 
to improve the clinical outcome of radiation therapy by 
enhancing radiosensitivity.
On the other hand, STAT3 and NF-κβ together with 
C/EBPβ act as master regulators of PMT [24, 31, 44]. 
In PG35-GICs-R these transcription factors and further 
PMT key pathways were significantly activated following 
RT. It is widely accepted that GBMs upon recurrence 
tend to shift from the PN toward the Mes subtype [45] 
and that RT can induce this transition in PN-GBM cells 
both in-vitro [46] and in-vivo [47]. Importantly, we show 
an enhancement of Mes signature upon RT also in our 
established Mes GICs, thus reinforcing the relevance of 
mesenchymal differentiation in GBM treatment resistance. 
Taken together, RT drives GICs toward an enriched Mes 
status independently of their original molecular subtype.
Following clinically relevant fractionated RT, our 
GICs but not DGC exhibited a significant upregulation of 
ICAM1, PLA2G4A, PTGS2, LIF, IL6 and NNMT genes, 
indicating GICs preferential activation of inflammatory 
pathways and NNMT-mediated SSB repair [48]. In 
addition, we found a greater IL6Rα expression in GICs 
compartment suggesting a higher responsiveness to 
secreted IL6-LIF and an effective IL6-LIF/STAT3 
autocrine loop. Moreover, we may speculate a juxtacrine 
effect of radiotherapy induced cytokines on stromal and 
cancer cells [49-51].Taken together, GICs secretome may 
drive a radiotherapy-induced shift toward a Mes status and 
the acquisition of a more aggressive phenotype. 
We should mention, however, some limitations 
of the study. Although our results clearly suggested a 
correlation between in-vitro GICs radioresistance and 
patient outcome, the sample size is relatively small and 
hence a larger set of paired samples would be necessary 
to confirm our findings. In addition, further experiments 
should be carried out to address the involvement of 
inflammatory pathways in GBM radioresistance and to 
provide additional insights. 
In summary, we propose an affordable in-vitro 
method as a tool to better understand the mechanism 
underlying GICs radioresistance and potentially predict 
patient response to RT based on empirical data. Our 
findings collectively support the leading role of GICs in 
defining patient treatment response and the relevance of 
targeting inflammatory and PMT signaling pathways in 
conjunction with radiation treatment.
MATERIALS AND METHODS
Primary glioblastoma cell cultures
Glioblastoma tumor samples (GBT) were collected 
during surgery from consenting patients according to the 
protocol approved by the Ethics Committee of Hospital 
Universitari de Bellvitge (HUB; histological diagnosis 
GBM WHO grade IV, IDH1-wt) [52]. The assessment 
of IDH1 status was carried out at the Pathology 
Department of the HUB. The presence of IDH1 point 
mutation at codon 132 (R132H) was evaluated through 
immunohistochemistry using a R132H mutation-specific 
antibody (clone H09; Optistain). GBT samples were 
processed within 1h and grown as DGC cultures [53], or 
as GICs following the neurosphere culture method [9, 54] 
(see also Supplementary Methods). 
Real-time q-PCR analyses
Total RNA was extracted from cells using TRIsure 
(Bioline). mRNA was treated with DNase I RNase-
free (Thermo Scientific) and retro-transcribed with 
High Capacity cDNA Reverse Transcription Kit (Life 
Technologies). Gene expression analyses were performed 
using validated Taqman® Gene Expression Assays 
(Applied Biosystems). Data analysis unless otherwise 
specified, was based on the ΔCt method with GAPDH 
and GUSB as housekeeping genes. Metagene score of 
molecular subtypes was calculated [24].
Western blot
Proteins were extracted with 0.3% CHAPs buffer 
supplemented with protease inhibitors. Densitometric 
analysis was carried out using Multi-Gauge software 
(FujiFilm Corporation). Further details for the specific 
antibodies are given in Supplementary Methods.
Soft agar assay
Soft agar assay was performed over a 0.5% agar 
layer, with single-cell suspension dissolved in 0.3% agar. 
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Cells were maintained in culture for three weeks and then 
stained with MTT 0.5 mg/ml for six hours. The number 
of stained colonies was scored with ImageJ (NIH, USA). 
Clonogenic capacity
GICs were seeded in 96-well plates as single-
cell suspension at low densities in triplicate. Cells were 
maintained for 14 days in their culturing media and then 
plates were visually scanned under light microscope. 
Neurospheres bigger than 100 µm were scored (ProgRes 
CapturePro). DGC were seeded in 6-well plates in 
triplicate and cells were stained after 14 days with 
0.2% crystal violet and fixed with 2% ethanol. Colonies 
containing more than 50 cells were scored.
Radiation schedule
Treatment of cells was carried out using an X-ray 
accelerator (Clinac 600 CD, M/S Varian AG) at a dose-rate 
of 2.67 Gy/min. Samples were irradiated every 24 hours 
following a fractionated schedule, using 2.0 Gy/fraction 
as repeated dose. Dosimetry calculations were performed 
by the Medical Physics Department at the Catalan Institute 
of Oncology.
Clonogenic assay
To determine the radiation sensitivity of DGC 
cultures, clonogenic assay was performed as described 
[53]. For GICs cultures, the assay was adapted to the 
condition of free-floating spheres. GICs were seeded 
at low density (40 and 80 cells/well) in 96-well flat-
bottomed plates and exposed to RT schedule 24 hours 
later. Following 14 days, the total number of newly formed 
neurospheres and colonies was recorded as indicated 
for clonogenic capacity assessment. Further details on 
the survival curve analysis are given in Supplementary 
Methods.
Microarray analysis
A total of 100-300 ng of RNA was labelled using the 
WT Expression Kit (Ambion) and hybridized to Human 
Gene 1.0 ST Array (Affymetrix). Data were analyzed 
with Microarray Suite version 5.0 (MAS 5.0) using 
Affymetrix default analysis settings and global scaling 
as normalization method. The data were deposited under 
the GEO reference GSE82139 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?token = snclwmaerjytlyl&acc = 
GSE82139). The Gene Set Expression Analysis (GSEA) 
tool was run using default values for all parameters [55]. 
GSEA was interrogated using GSEA Hallmarks and 
transcription factor target (GSEA-TFT) enrichment and 
pathway annotation from Kyoto Encyclopedia of Genes 
and Genomes (KEGG), BioCarta (National Cancer 
Institute), and Reactome. Principal Component Analysis 
(PCA), unsupervised hierarchical clustering and heatmaps 
were obtained using the R (http://www.r-project. org/). 
Statistical analysis
Data graphs are presented as means ± SEM. 
Statistical analyses were performed using GraphPad 
Prism® software. 
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